Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells

by Anna Euteneuer, University of Cologne

edited by Sadie Harley, reviewed by Robert Egan

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

An international research team led by Dr. Lucia Torres Fernández from the working groups of Professor Dr. Julie George and Professor Dr. Roman Thomas at the University of Cologne has identified a critical dependency in small cell lung cancer (SCLC) that can be exploited therapeutically.

The study, published in the journal Molecular Cancer, demonstrates for the first time that SCLC tumor cells rely on the nonsense-mediated mRNA decay (NMD) pathway to cope with their extremely high mutation burden.

This mechanism enables tumor cells to break down harmful mutated products, thereby ensuring their survival; at the same time, however, it makes them vulnerable to new therapeutic approaches.

Small cell lung cancer is among the types of cancer with the highest mutation rates. Normally, a mutation burden of this kind would be fatal to cells, but SCLC tumor cells have found a way to adapt to it: They use the NMD signaling pathway to efficiently degrade mutated and potentially harmful gene products.

In this way, they not only avoid the accumulation of toxic protein variants that would jeopardize their growth, but they also prevent abnormal protein fragments from being recognized by the surrounding elements of the immune system.

"This extreme dependence on NMD is an Achilles' heel of SCLC cells," explains George, senior author of the study and co-lead of the project. "Without NMD, the cells would be unable to tolerate their high mutation burden, and it is precisely this vulnerability that offers a promising avenue for new therapies."

Using experimental models, the team demonstrated that the pharmacological inhibition of NMD—specifically through the inhibition of the key NMD kinase SMG1—has two crucial effects: first, the accumulation of mutated proteins in the tumor cells, which leads to stress and ultimately to the death of the cancer cells; and second, increased presentation of abnormal peptides on the cell surface, which are recognized as foreign by the immune system, in particular by cytotoxic T cells.

"Inhibiting NMD suddenly turns an 'immunocold' tumor such as SCLC into a cancer that can be attacked," emphasizes Torres Fernández, the study's lead author.

"SCLC was long considered resistant to immunotherapy because it is scarcely recognized by the immune system. Our data suggest that the tumor actively 'disguises' itself by using NMD as a protective shield. If this signaling pathway is blocked, the cancer becomes detectable to the immune system."

SMG1 inhibition: A new step in the fight against cancer?

The results open up promising prospects for clinical application. The targeted inhibition of SMG1 could not only lead directly to the death of cancer cells but also enable combination therapies with immune checkpoint inhibitors.

"This could make SCLC—one of the most aggressive forms of cancer—a candidate for T-cell-based therapies," says Thomas, head of the Department of Translational Genomics and co-senior author.

"Genomic instability and the associated increased mutation burden are key characteristics of many cancers. As healthy cells require only small amounts of NMD, this form of treatment could be particularly well targeted and tolerated."

These findings are currently being investigated further as part of the Collaborative Research Center (SFB) 1399, "Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer."

"Our aim is to bring new approaches into clinical practice as quickly as possible for the benefit of patients," says Thomas.

Publication details

Lucia A. Torres-Fernández et al, A targetable dependency on nonsense-mediated decay for cellular homeostasis and immune control in small cell lung cancer, Molecular Cancer (2026). DOI: 10.1186/s12943-026-02750-2

Journal information: Molecular Cancer

Key medical concepts

Small Cell Lung CarcinomaT-Lymphocytes, Cytotoxic

Clinical categories

OncologyPulmonary medicine Provided by University of Cologne Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells (2026, September 9) retrieved 9 September 2026 from https://medicalxpress.com/news/2026-09-cancer-shield-blocking-pathway-small.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.